Comparison between Dr.Lal PathLabs IPO and TeamLease IPO.
Dr.Lal PathLabs IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while TeamLease IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Dr.Lal PathLabs IPO is up to ₹631.91 Cr whereas the issue size of the TeamLease IPO is up to ₹423.68 Cr. The final issue price of Dr.Lal PathLabs IPO is ₹550.00 per share and of TeamLease IPO is ₹850.00 per share.
| Dr.Lal PathLabs IPO | TeamLease IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹540.00 per share | ₹785.00 per share |
| Issue Price (Upper) | ₹550.00 per share | ₹850.00 per share |
| Issue Price (Final) | ₹550.00 per share | ₹850.00 per share |
| Discount (Retail) | ₹15.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 20 shares | 15 shares |
| Fresh Issue Size | 0 shares | 17,64,705 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹150.00 Cr |
| OFS Issue Size | 1,16,00,000 shares | 32,19,733 shares |
| OFS Issue Size (Amount) | up to ₹631.91 Cr | up to ₹273.68 Cr |
| Issue Size Total | 1,16,00,000 shares | 49,84,438 shares |
| Issue Size Total (Amount) | up to ₹631.91 Cr | up to ₹423.68 Cr |
Dr.Lal PathLabs IPO opens on Dec 08, 2015, while TeamLease IPO opens on Feb 02, 2016. The closing date of Dr.Lal PathLabs IPO and TeamLease IPO is Dec 10, 2015, and Feb 04, 2016, respectively.
| Dr.Lal PathLabs IPO | TeamLease IPO | |
|---|---|---|
| Anchor Bid Date | Dec 07, 2015 | Feb 01, 2016 |
| Issue Open | Dec 08, 2015 | Feb 02, 2016 |
| Issue Close | Dec 10, 2015 | Feb 04, 2016 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | Dec 23, 2015 | Feb 12, 2016 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Dr.Lal PathLabs IPO P/E ratio is , as compared to TeamLease IPO P/E ratio of .
| Dr.Lal PathLabs IPO | TeamLease IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 63.67 | 51.86 | ||||
| Promoter Shareholding (Post-Issue) | 58.7 | 19.99 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹4545.46 Cr. | ₹1453.23 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW | 27.85% |
In the Dr.Lal PathLabs IPO Retail Individual Investors (RII) are offered 40,60,000 shares while in TeamLease IPO retail investors are offered 40,60,000 shares. Qualified Institutional Buyers (QIB) are offered 23,20,000 shares in Dr.Lal PathLabs IPO and 14,92,345 shares in TeamLease IPO.
| Dr.Lal PathLabs IPO | TeamLease IPO | |
|---|---|---|
| Anchor Investor Reservation | 34,80,000 shares | 22,38,498 shares |
| Market Maker Reservation | ||
| QIB | 23,20,000 shares | 14,92,345 shares |
| NII | 17,40,000 shares | 7,46,165 shares |
| RII | 40,60,000 shares | 4,97,430 shares |
| Employee | 10,000 shares | |
| Others | ||
| Total | 1,16,00,000 shares | 49,84,438 shares |
Dr.Lal PathLabs IPO subscribed 33.41x in total, whereas TeamLease IPO subscribed 66.02x.
| Dr.Lal PathLabs IPO | TeamLease IPO | |
|---|---|---|
| QIB (times) | 63.56x | 26.97x |
| NII (times) | 61.28x | 185.24x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 4.24x | 10.61x |
| Employee (times) | 1.39x | |
| Other (times) | ||
| Total (times) | 33.41x | 66.02x |
